Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Zomedica stock price, quote, forecast and news

ZOM
CA98980M1095
A2QEF3

Price

0.13
Today +/-
-0.00
Today %
-0.30 %
P

Zomedica stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Zomedica stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Zomedica stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Zomedica stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Zomedica's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Zomedica Stock Price History

DateZomedica Price
9/13/20240.13 undefined
9/12/20240.13 undefined
9/11/20240.13 undefined
9/10/20240.13 undefined
9/9/20240.13 undefined
9/6/20240.13 undefined
9/5/20240.13 undefined
9/4/20240.12 undefined
9/3/20240.12 undefined
8/30/20240.13 undefined
8/29/20240.13 undefined
8/28/20240.13 undefined
8/27/20240.13 undefined
8/26/20240.13 undefined
8/23/20240.14 undefined
8/22/20240.14 undefined
8/21/20240.14 undefined
8/20/20240.14 undefined
8/19/20240.14 undefined
8/16/20240.14 undefined

Zomedica Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Zomedica, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Zomedica from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Zomedica’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Zomedica. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Zomedica’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Zomedica’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Zomedica’s growth potential.

Zomedica Revenue, EBIT and net profit per share

DateZomedica RevenueZomedica EBITZomedica Net Income
2026e50.07 M undefined3.07 M undefined0 undefined
2025e39.58 M undefined-2.19 M undefined0 undefined
2024e34.44 M undefined-5.1 M undefined-9.9 M undefined
202325.19 M undefined-31.59 M undefined-34.53 M undefined
202218.93 M undefined-21.92 M undefined-17.02 M undefined
20214.13 M undefined-21.37 M undefined-18.38 M undefined
20200 undefined-16.76 M undefined-16.91 M undefined
20190 undefined-19.78 M undefined-19.78 M undefined
20180 undefined-16.58 M undefined-16.65 M undefined
20170 undefined-8.08 M undefined-8.07 M undefined
20160 undefined-5.73 M undefined-5.74 M undefined
20150 undefined-56,222 undefined-56,222 undefined
20140 undefined-39,892 undefined-39,892 undefined
20130 undefined-80,000 undefined-80,000 undefined
20120 undefined0 undefined0 undefined

Zomedica Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e
00000000041825343950
----------350.0038.8936.0014.7128.21
---------75.0072.2268.00---
00000000031317000
0000-5-8-16-19-16-21-21-31-5-23
----------525.00-116.67-124.00-14.71-5.136.00
0000-5-8-16-19-16-18-17-34-900
-----60.00100.0018.75-15.7912.50-5.56100.00-73.53--
0.80.341180.1687.493.44106.3364.44956.53979.92979.95000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Zomedica Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Zomedica is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201220132014201520162017201820192020202120222023
                       
0.080.210.130.083.233.451.940.5161.99194.95115.0990.5
00000.020.030.050.070.150.771.862.2
000000000000
0000000002.852.755.12
00000.330.791.871.230.731.843.82.06
0.080.210.140.083.584.263.861.8162.87200.41123.599.88
00000.290.370.721.831.92.539.1725.29
000000000040.7110.01
0000000000.451.270
00000.320.020.010.540.3833.5241.855.36
00000000043.2963.9861.58
0.020000.690.571.44010.660.451.07
0.020001.30.952.172.383.2880.44157.38153.32
0.10.210.140.084.885.226.034.1866.14280.85280.88253.2
                       
0.10.260.210.2210.1918.2430.4150.53116.75380.96380.97380.97
000001.771.243.6314.799.3123.6729.93
0-0.08-0.11-0.16-7.53-15.63-27.99-52.06-68.51-119.39-136.4-170.93
00.0300.021.4800000-0.840.05
000000000000
0.10.210.110.084.134.393.662.163.03270.89267.39240.02
00.0100.010.730.832.382.091.253.236.77.67
000000000239.92187981
000000000459.73285383
00000000527.36000
00000000252.79414.76410
00.0100.010.730.832.382.092.034.347.819.03
00000.010001.090.961.10
0000000003.711.251.14
0000000000.52.073.01
00000.010001.095.174.414.15
00.0100.010.740.832.382.093.129.5112.2213.18
0.10.220.110.084.885.226.034.1866.14280.4279.61253.2
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Zomedica provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Zomedica's financial health and stability.

Assets

Zomedica's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Zomedica must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Zomedica after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Zomedica's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (k)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201220132014null2015null2016201720182019202020212022
000000-5-8-16-19-16-18-17
0000000000014
00000000000-2-2
0000000000-1-1-3
000000215531314
0000000000000
0000000000000
000000-4-7-11-15-16-14-11
000000000000-2
00000000001,000-71,000-155,000
00000000001,000-71,000-153,000
0000000000000
0000000000000
00000000212812330
000000471014762190
0000004682-5-140
0000000000000
00000000-1-161132-167
0-0.07-0.040-0.050-4.8-7.26-11.78-16.32-16.26-14.8-14.46
0000000000000

Zomedica stock margins

The Zomedica margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Zomedica. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Zomedica.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Zomedica's sales revenue. A higher gross margin percentage indicates that the Zomedica retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Zomedica's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Zomedica's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Zomedica's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Zomedica. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Zomedica's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Zomedica Margin History

Zomedica Gross marginZomedica Profit marginZomedica EBIT marginZomedica Profit margin
2026e68.76 %6.14 %0 %
2025e68.76 %-5.54 %0 %
2024e68.76 %-14.8 %-28.74 %
202368.76 %-125.43 %-137.1 %
202272.12 %-115.81 %-89.88 %
202173.89 %-516.99 %-444.78 %
202068.76 %0 %0 %
201968.76 %0 %0 %
201868.76 %0 %0 %
201768.76 %0 %0 %
201668.76 %0 %0 %
201568.76 %0 %0 %
201468.76 %0 %0 %
201368.76 %0 %0 %
201268.76 %0 %0 %

Zomedica Stock Sales Revenue, EBIT, Earnings per Share

The Zomedica earnings per share therefore indicates how much revenue Zomedica has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Zomedica earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Zomedica's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Zomedica’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zomedica's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Zomedica Revenue, EBIT and net profit per share

DateZomedica Sales per ShareZomedica EBIT per shareZomedica Earnings per Share
2026e0.05 undefined0 undefined0 undefined
2025e0.04 undefined0 undefined0 undefined
2024e0.04 undefined0 undefined-0.01 undefined
20230.03 undefined-0.03 undefined-0.04 undefined
20220.02 undefined-0.02 undefined-0.02 undefined
20210 undefined-0.02 undefined-0.02 undefined
20200 undefined-0.05 undefined-0.05 undefined
20190 undefined-0.19 undefined-0.19 undefined
20180 undefined-0.18 undefined-0.18 undefined
20170 undefined-0.09 undefined-0.09 undefined
20160 undefined-0.07 undefined-0.07 undefined
20150 undefined-0.06 undefined-0.06 undefined
20140 undefined-0.04 undefined-0.04 undefined
20130 undefined-0.24 undefined-0.24 undefined
20120 undefined0 undefined0 undefined

Zomedica business model

Zomedica Corp is an emerging company specializing in the development and marketing of innovative diagnostics and treatment options for pets. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan. Zomedica's business model is primarily focused on providing better diagnostics and therapy for pets to veterinarians and pet owners. The company develops and markets veterinary diagnostics and precise treatment solutions for various diseases in pets. Zomedica is divided into different divisions specializing in different areas of veterinary diagnostics and therapy. One of these divisions is "Point-of-Care" diagnostics, which allows veterinarians to perform quick and accurate diagnoses directly in their practice. Zomedica offers innovative devices and tests for the rapid diagnosis of diseases such as prostatitis or hypothyroidism. Another important division is "Companion Diagnostic" diagnostics, which is specifically focused on the diagnosis of cancer in pets. Zomedica has developed innovative tests that enable quick and precise diagnoses, allowing for targeted therapy initiation. In addition to diagnostics, Zomedica also offers innovative therapy solutions for pets. The company focuses on the development of antibiotics for animals, as well as precise treatment solutions for diseases such as diabetes or chronic kidney disease. One of Zomedica's best-known products is TRUFORMA, an innovative diagnostic device for veterinarians that enables quick and precise diagnosis of various diseases. The company has also developed a range of tests for the diagnosis of thyroid disease, prostatitis, and diabetes. In recent years, Zomedica has become one of the leading companies in veterinary diagnostics and therapy and has already convinced numerous veterinarians and pet owners of its innovative products and solutions. The company relies on close collaboration with veterinarians to continuously improve its products and tailor them to the needs of the market. Overall, Zomedica is an innovative company specializing in products and solutions for the needs of veterinarians and pet owners. With its innovative diagnostics and treatment solutions, the company is setting new standards in veterinary medicine and contributing to the improvement of pet health worldwide. Zomedica is one of the most popular companies on Eulerpool.com.

Zomedica SWOT Analysis

Strengths

Zomedica Corp has a strong brand reputation within the animal health industry, providing it with a competitive advantage.

The company has a dedicated and experienced team of professionals who possess deep knowledge of the veterinary sector.

Zomedica Corp maintains strong relationships with key industry stakeholders, including veterinarians and distributors.

Weaknesses

The company faces significant competition from well-established players in the animal health market, which may pose challenges to its market share.

Zomedica Corp has a limited product portfolio, which restricts its ability to cater to a wider range of customer needs and preferences.

The company's financial resources are relatively constrained compared to larger competitors, impacting its ability to invest in research and development.

Opportunities

The global animal health market is expected to experience steady growth, presenting an opportunity for Zomedica Corp to expand its customer base and revenue.

The increasing pet ownership trend and rising focus on animal wellness provide the company with an opportunity to introduce innovative products that cater to these consumer demands.

Zomedica Corp can explore strategic partnerships and collaborations to access new markets and enhance its product offerings.

Threats

Regulatory compliance within the animal health industry presents a challenge to Zomedica Corp, as non-compliance could lead to legal and financial repercussions.

The ongoing COVID-19 pandemic has disrupted supply chains and veterinary services, potentially impacting the company's operations and revenue streams.

Increased price competition and the threat of substitution from generic veterinary products could negatively impact Zomedica Corp's market position.

Zomedica Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Zomedica historical P/E ratio, EBIT, and P/S ratio.

Zomedica shares outstanding

The number of shares was Zomedica in 2023 — This indicates how many shares 979.95 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Zomedica earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Zomedica's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Zomedica’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zomedica's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Zomedica.

Zomedica latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240 0  (0 %)2024 Q2
3/31/20240 -0.01  (0 %)2024 Q1
12/31/20230 -0.01  (0 %)2023 Q4
9/30/20230 -0  (0 %)2023 Q3
6/30/20230 -0.01  (0 %)2023 Q2
3/31/20230 -0.01  (0 %)2023 Q1
12/31/2022-0.01 -0.01  (40.59 %)2022 Q4
12/31/20200 -0.01  (0 %)2020 Q4
9/30/20200 -0.01  (0 %)2020 Q3
6/30/2020-0.01 -0.02  (-98.02 %)2020 Q2
1
2

Zomedica list of shareholders

%
Name
Stocks
Change
Date
4.99042 % The Vanguard Group, Inc.48,903,65195,66212/31/2023
1.13475 % Rowe Family GST Trust11,120,00001/9/2024
1.06032 % BlackRock Institutional Trust Company, N.A.10,390,650012/31/2023
1.03281 % Geode Capital Management, L.L.C.10,120,991480,00912/31/2023
0.33896 % State Street Global Advisors (US)3,321,681012/31/2023
0.26265 % ProShare Advisors LLC2,573,819-414,46212/31/2023
0.25170 % Brown Brothers Harriman & Company2,466,532012/31/2023
0.19899 % Powers (Johnny D)1,950,00001/9/2024
0.18379 % Northern Trust Investments, Inc.1,801,06113,15412/31/2023
0.11434 % Rowe (Jeffrey Mark)1,120,48001/9/2024
1
2
3
4
5
...
10

Zomedica Executives and Management Board

Mr. Larry Heaton66
Zomedica Chief Executive Officer
Compensation 1.34 M
Mr. Robert Cohen65
Zomedica Director (since 2020)
Compensation 847,898
Mr. Adrian Lock61
Zomedica Vice President, General Manager, Chief Executive Officer of Pulse Veterinary Technologies, LLC
Compensation 444,517
Mr. Jeffrey Rowe67
Zomedica Independent Chairman of the Board
Compensation 262,500
Mr. Christopher Macleod53
Zomedica Independent Director
Compensation 262,500
1
2
3

Zomedica Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Qorvo Stock
Qorvo
SupplierCustomer0,600,750,880,740,860,59
SANUWAVE Health Stock
SANUWAVE Health
SupplierCustomer-0,540,270,830,580,44-
1

Most common questions regarding Zomedica

What values and corporate philosophy does Zomedica represent?

Zomedica Corp represents values of innovation, dedication, and excellence in the field of animal health. With a commitment to advancing veterinary diagnostics and pharmaceuticals, Zomedica strives to improve the quality of care for companion animals. The company's corporate philosophy revolves around providing accessible and effective solutions for veterinarians, empowering them to make informed decisions and deliver optimal healthcare. Zomedica Corp's mission is to enhance the overall well-being of animals by developing and commercializing innovative products that address unmet needs in the veterinary industry. Through their cutting-edge technologies and passion for animal welfare, Zomedica Corp continues to establish itself as a leader in the veterinary healthcare sector.

In which countries and regions is Zomedica primarily present?

Zomedica Corp is primarily present in the United States.

What significant milestones has the company Zomedica achieved?

Zomedica Corp has achieved several significant milestones since its establishment. One notable milestone is the successful development and commercialization of its flagship product, TRUFORMA. This innovative point-of-care diagnostic platform offers veterinarians real-time, on-site diagnostic capabilities, enhancing patient care and improving treatment outcomes. Another crucial milestone for Zomedica Corp is the expansion of its commercial partnerships and collaborations. These alliances have allowed the company to extend its global reach and leverage its technology in various veterinary markets. Furthermore, Zomedica Corp has recently attained regulatory approvals and certifications, ensuring its products meet the highest quality standards. These milestones highlight Zomedica Corp's commitment to advancing veterinary diagnostics and delivering cutting-edge solutions to the market.

What is the history and background of the company Zomedica?

Zomedica Corp is a company specializing in veterinary health products. Established in 2015, Zomedica focuses on developing and commercializing innovative solutions for companion animals, addressing various healthcare needs. With a commitment to advancing animal health, Zomedica aims to improve the quality of veterinary care through its diagnostic and therapeutic products. The company has forged partnerships with industry leaders and experts to drive research and development efforts. Zomedica Corp remains dedicated to enhancing the well-being of animals, contributing to the advancement of veterinary medicine.

Who are the main competitors of Zomedica in the market?

The main competitors of Zomedica Corp in the market include veterinary pharmaceutical companies such as Zoetis Inc., IDEXX Laboratories, and Elanco Animal Health. These companies, like Zomedica Corp, provide products and services focused on improving animal health and wellness. Zomedica Corp aims to differentiate itself by offering innovative diagnostic and treatment solutions tailored to the unique needs of veterinarians. With a focus on research and development, Zomedica Corp strives to stay competitive in the market by delivering advanced and effective solutions for animal care.

In which industries is Zomedica primarily active?

Zomedica Corp is primarily active in the animal health industry.

What is the business model of Zomedica?

The business model of Zomedica Corp primarily focuses on developing and commercializing innovative veterinary diagnostic and treatment solutions. Zomedica aims to provide veterinarians with advanced and accessible tools to enhance the quality of care for companion animals. By leveraging its expertise in diagnostics, Zomedica aims to revolutionize veterinary medicine by delivering precise and timely diagnostic results. The company's product portfolio includes diagnostics platforms and novel therapeutics, all designed to meet the unique needs of veterinarians and their patients. Zomedica's business model is centered around driving growth through the development and commercialization of cutting-edge veterinary solutions.

What is the P/E ratio of Zomedica 2024?

The Zomedica P/E ratio is -13.08.

What is the P/S ratio of Zomedica 2024?

The Zomedica P/S ratio is 3.76.

What is the AlleAktien quality score of Zomedica?

The AlleAktien quality score for Zomedica is 4/10.

What is the revenue of Zomedica 2024?

The expected Zomedica revenue is 34.44 M USD.

How high is the profit of Zomedica 2024?

The expected Zomedica profit is -9.9 M USD.

What is the business model of Zomedica

The Zomedica Corporation is an innovative company operating in the field of veterinary medicine. Its business model is based on creating products in the veterinary market that meet the needs of veterinarians and pet owners. The main products offered by Zomedica Corp include diagnostic and treatment solutions for domestic, farm, and laboratory animals. The company has satisfied these needs with its products. One important aspect of Zomedica Corp is the manufacturing of diagnostic products. Veterinarians require accurate and reliable results from laboratory tests to make medical decisions. Zomedica Corp has developed diagnostic tests that provide precise and rapid results to help veterinarians make quick decisions. These tests allow veterinarians to make accurate diagnoses of diseases in animals. The company has also developed innovative treatment solutions for animals. One of the main causes of diseases and deteriorating health in animals is the food they consume. Therefore, Zomedica Corporation has developed a product line called TRUFORMA, which offers species-appropriate food and specialized supplements. TRUFORMA is based on a patented formula that is specifically tailored to the needs of animals and supports a balanced diet. Additionally, the company also provides animal health services to assist veterinarians in the diagnosis and treatment of animals. Veterinarians can utilize Zomedica Corp's telemedicine platform to communicate with specialists around the world and engage in discussions. The platform also offers training and continuing education on animal health. In summary, the business model of Zomedica Corp is focused on providing veterinarians and pet owners with products and services tailored to the needs of their pets. The company develops innovative diagnostic and treatment solutions, including specialized nutrition and health services, enabling veterinarians to offer an optimally matched lifestyle for caring pet owners.

What is the Zomedica dividend?

Zomedica pays a dividend of 0 USD distributed over payouts per year.

How often does Zomedica pay dividends?

The dividend cannot currently be calculated for Zomedica or the company does not pay out a dividend.

What is the Zomedica ISIN?

The ISIN of Zomedica is CA98980M1095.

What is the Zomedica WKN?

The WKN of Zomedica is A2QEF3.

What is the Zomedica ticker?

The ticker of Zomedica is ZOM.

How much dividend does Zomedica pay?

Over the past 12 months, Zomedica paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zomedica is expected to pay a dividend of 0 USD.

What is the dividend yield of Zomedica?

The current dividend yield of Zomedica is .

When does Zomedica pay dividends?

Zomedica pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zomedica?

Zomedica paid dividends every year for the past 0 years.

What is the dividend of Zomedica?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zomedica located?

Zomedica is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zomedica kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zomedica from 9/14/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/14/2024.

When did Zomedica pay the last dividend?

The last dividend was paid out on 9/14/2024.

What was the dividend of Zomedica in the year 2023?

In the year 2023, Zomedica distributed 0 USD as dividends.

In which currency does Zomedica pay out the dividend?

The dividends of Zomedica are distributed in USD.

All fundamentals about Zomedica

Our stock analysis for Zomedica Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zomedica Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.